Evaxion teases 67% response rate in PhI metastatic melanoma trial

Paul Schloesser

Associate Editor

Evaxion Biotech said eight of 12 patients with metastatic melanoma who received a combination of the lead candidate and an unnamed checkpoint inhibitor had a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Evaxion teases 67% response rate in PhI metastatic melanoma trial

Paul Schloesser

Associate Editor

Sign up to read this article for free.

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Evax­ion teas­es 67% re­sponse rate in PhI metasta­t­ic melanoma tri­al

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

Large vac­cine mak­ers stand by their in­vest­ments de­spite US head­winds

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Genen­tech vet launch­es ADC start­up with $20M

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

Evaxion teases 67% response rate in PhI metastatic melanoma trial

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence